Clinical Trial Update: A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) [Phase 1]

View source ↗

Summary

Phase 1 Breakfree-1 trial evaluating CC-97540, a CD-19-targeted Nex-T CAR T cell therapy, for severe, refractory autoimmune diseases; the study is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathy
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• CC-97540

Snippet

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy | Phase 1 | Status: RECRUITING